Evidence map›Paper›PMID 34807493›Full record

ArticleCancer science2022

Dvl2 facilitates the coordination of NF-κB and Wnt signaling to promote colitis-associated colorectal progression.

Feiyu Tang, Fuyang Cao, Can Lu, Xiang He, Liang Weng, Lunquan Sun

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. CD44British journal of cancer · 2025
    Article
  5. Article
  6. Review
  7. Adaptor protein Abelson interactor 1 in homeostasis and disease.Cell communication and signaling : CCS · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Feiyu TangDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-0380-9537
Fuyang CaoDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-1096-268X
Can LuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-0898-1854
Xiang HeDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-3784-105X
Liang WengDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0001-7058-8274
Lunquan SunDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0002-0749-1995
Central South University · CN

Funding

Hunan Province Natural Science Funds for Excellent Young Scholars 2019JJ30043National Natural Science Foundation of China 81530084National Natural Science Foundation of China 81900199National Natural Science Foundation of China 81974465National Natural Science Foundation of China 82030087recruitment program for Huxiang Talents 2019RS1009
6 · The paper itself

Abstract

Colitis-associated colorectal cancer (CAC) arises due to prolonged inflammation and has distinct molecular events compared with sporadic colorectal cancer (CRC). Although inflammatory NF-κB signaling was activated by pro-inflammatory cytokines (such as TNFα) in early stages of CAC, Wnt/β-catenin signaling later appears to function as a key regulator of CAC progression. However, the exact mechanism responsible for the cross-regulation between these 2 pathways remains unclear. Here, we found reciprocal inhibition between NF-κB and Wnt/β-catenin signaling in CAC samples, and the Dvl2, an adaptor protein of Wnt/β-catenin signaling, is responsible for NF-κB inhibition. Mechanistically, Dvl2 interacts with the C-terminus of tumor necrosis factor receptor 1 (TNFRI) and mediates TNFRI endocytosis, leading to NF-κB signal inhibition. In addition, increased infiltration of the pro-inflammatory cytokine interleukin-13 (IL-13) is responsible for upregulating Dvl2 expression through STAT6. Targeting STAT6 effectively decreases Dvl2 levels and restrains colony formation of cancer cells. These findings demonstrate a unique role for Dvl2 in TNFRI endocytosis, which facilitates the coordination of NF-κB and Wnt to promote CAC progression.

Indexed as

AnimalsCell Line, TumorColitis-Associated NeoplasmsCytokinesDisease ProgressionDishevelled ProteinsEndocytosisGene Expression Regulation, NeoplasticHumansInflammationMiceNF-kappa BReceptors, Tumor Necrosis Factor, Type ISignal TransductionTumor Necrosis Factor-alphaWnt ProteinsCytokinesDishevelled ProteinsDVL2 protein, humanNF-kappa BReceptors, Tumor Necrosis Factor, Type ITNF protein, humanTNFRSF1A protein, humanTumor Necrosis Factor-alphaWnt ProteinsDvl2endocytosisinflammationNF-κBTNFRIWnt

Identifiers

PMID34807493
PMCPMC8819304
OpenAlexW3217651316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.